Breaking News

MorphoSys, Boehringer Sign Manufacturing Pact

MorphoSys AG and Boehringer Ingelheim have signed a manufacturing agreement for therapeutic antibodies covering the process development and manufacture of additional clinical material for MorphoSys’s MOR208 program and other drug candidates.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MorphoSys AG and Boehringer Ingelheim have signed a manufacturing agreement for therapeutic antibodies covering the process development and manufacture of additional clinical material for MorphoSys’s MOR208 program and other drug candidates. MOR208 is a potent monoclonal anti-CD19 antibody in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently in Phase I development in the U.S. by MorphoSys’s partner Xencor, Inc. “A...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters